BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $207,817.32 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BioLife Solutions Stock Up 4.9 %

Shares of NASDAQ:BLFS opened at $27.39 on Friday. The stock has a market capitalization of $1.27 billion, a P/E ratio of -25.84 and a beta of 1.91. The stock’s 50-day moving average price is $24.96 and its 200-day moving average price is $23.72. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $28.88.

Analyst Ratings Changes

BLFS has been the topic of several research analyst reports. TD Cowen upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright lowered their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. KeyCorp upped their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday. Finally, Craig Hallum lifted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of BioLife Solutions during the third quarter valued at approximately $28,000. Isthmus Partners LLC raised its stake in shares of BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 42,265 shares during the last quarter. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions during the second quarter worth about $35,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions in the third quarter worth about $57,000. Finally, GAMMA Investing LLC increased its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the period. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.